Skip to main content
OpenTrials
Completed

NCT Number: NCT02192333

Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors

This randomized clinical trial studies survivorship care in reducing symptoms in young adult cancer survivors. Survivorship care programs that identify the needs of young adult cancer survivors and ways to support them through the years after treatment may help reduce symptoms, such as pain, fatigue, sleep disturbance, depression, and distress, in young adult cancer survivors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Carcinoma Behavior Behavioral Symptoms Bone Diseases Bone Neoplasms Breast Diseases Breast Neoplasms Cancer Survivor Depression Digestive System Diseases Digestive System Neoplasms Fatigue Gastrointestinal Diseases Gastrointestinal Neoplasms Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Lymphatic Diseases Lymphoma Lymphoproliferative Disorders Malignant Bone Neoplasm Malignant Digestive System Neoplasm Malignant Female Reproductive System Neoplasm Malignant Male Reproductive System Neoplasm Mental Disorders Musculoskeletal Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Connective and Soft Tissue Nervous System Diseases Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Sarcoma Signs and Symptoms Skin Diseases Skin and Connective Tissue Diseases Sleep Disorder Sleep Wake Disorders Soft Tissue Sarcoma

Age range

18 year–39 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Loading trial locations.

About this study

PRIMARY OBJECTIVES:

I. To test the impact of providing the essential elements of survivorship care on survivorship outcomes as indicated by reduction in symptoms (pain, fatigue, sleep disturbance, depression, distress) in young adult cancer survivors diagnosed with cancer between the ages of 18 and 39 years when compared with usual care.

SECONDARY OBJECTIVES:

I. To improve confidence in survivorship knowledge and promote healthy lifestyle behaviors.

II. To provide evidence on barriers, needs and care preferences that will support long term follow-up recommendations for this population.

OUTLINE: Participants categorized as high-need are randomized to 1 of 2 arms. Participants categorized as low-need are assigned to Arm I.

ARM I: Participants receive usual care. After 12 months, participants may receive a survivorship clinic visit and boosters as in Arm II.

ARM II: Participants attend a survivorship clinic visit that includes care plans, screening recommendations, physician coordination, health promotion education, symptom management and palliative care, late effects education, psychosocial and medical assessments, and referrals for services and care as appropriate. Participants also receive phone-based survivorship boosters over approximately 15-30 minutes at 4-8 weeks and 12-16 weeks after the initial clinic visit.

After completion of study, participants are followed up at 6 and 12 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients enrolled on phase 1 of the study are eligible (and/or if recruited from tumor registry or clinic follow-up schedules)
  • Diagnosed with invasive malignancy including: breast, gastrointestinal track, female or male genitourinary system, sarcoma of bone or soft-tissue, leukemia and lymphoma
  • Treated at one of the Survivorship Centers of Excellence or their community affiliates
  • Received a therapeutic intervention with at least one of the following modalities: surgery, cytotoxic chemotherapy, biological or targeted agents, radiation therapy (any modality)
  • Currently between 1.0 and 4.99 years from the completion of active cancer-directed therapy (cytotoxic chemotherapy, radiation therapy and/or definitive surgical intervention)
  • Patient must still be in active follow-up: seen for a follow-up visit in the participating center at least once in the 3 years prior to enrollment and/or scheduled to be seen for follow-up in the next 6 months (i.e. in active follow-up)
  • May be receiving "maintenance" therapy that has a goal of prevention of recurrence but there should be no expectations for further active treatment
  • Able to read and speak English adequate to complete the patient-reported outcomes (PRO) assessment

Exclusion criteria

  • Prior visit to a survivorship clinic or previously provided with a treatment summary and care plan

Treatment and study plan

management of therapy complications

Procedure

Receive survivorship care

Quality-of-Life Assessment

Other

Ancillary studies

Other names: Quality of Life Assessment

Questionnaire Administration

Other

Ancillary studies

Telephone-Based Intervention

Behavioral

Receive phone-based booster intervention

Primary outcomes

  1. Mean of the two z scores of the two highest scores for the symptoms that determined the participant's eligibility as "high need" assessed using patient-reported outcomes (PRO) survey

    Time frame: At 6 months

    Mean scores for the primary outcome measures will be compared between the study using standard methods. Two-sided significance levels will be set at an alpha level of 0.05.

Secondary outcomes

  1. Barriers to health care assessed using the patient-reported outcomes (PRO) survey

    Time frame: Up to 12 months

    Will be examined in an exploratory manner, utilizing similar methods as those described for the primary endpoints for dichotomized versions of the outcomes, using standard cutoff values, where available.

  2. Change in depression assessed using the patient-reported outcomes (PRO) survey

    Time frame: Baseline to up to 12 months

    Will be examined in an exploratory manner, utilizing similar methods as those described for the primary endpoints for dichotomized versions of the outcomes, using standard cutoff values, where available. The mean differences in other continuous valued outcomes will be evaluated using standard t-tests or linear regression models, as appropriate.

  3. Change in distress assessed using the patient-reported outcomes (PRO) survey

    Time frame: Baseline to up to 12 months

    Will be examined in an exploratory manner, utilizing similar methods as those described for the primary endpoints for dichotomized versions of the outcomes, using standard cutoff values, where available. The mean differences in other continuous valued outcomes will be evaluated using standard t-tests or linear regression models, as appropriate.

  4. Change in fatigue assessed using the patient-reported outcomes (PRO) survey

    Time frame: Baseline to up to 12 months

    Will be examined in an exploratory manner, utilizing similar methods as those described for the primary endpoints for dichotomized versions of the outcomes, using standard cutoff values, where available. The mean differences in other continuous valued outcomes will be evaluated using standard t-tests or linear regression models, as appropriate.

  5. Change in pain assessed using the patient-reported outcomes (PRO) survey

    Time frame: Baseline to up to 12 months

    Will be examined in an exploratory manner, utilizing similar methods as those described for the primary endpoints for dichotomized versions of the outcomes, using standard cutoff values, where available. The mean differences in other continuous valued outcomes will be evaluated using standard t-tests or linear regression models, as appropriate.

  6. Change in sleep assessed using the patient-reported outcomes (PRO) survey

    Time frame: Baseline to up to 12 months

    Will be examined in an exploratory manner, utilizing similar methods as those described for the primary endpoints for dichotomized versions of the outcomes, using standard cutoff values, where available. The mean differences in other continuous valued outcomes will be evaluated using standard t-tests or linear regression models, as appropriate.

  7. Confidence in survivorship information assessed using the patient-reported outcomes (PRO) survey

    Time frame: Up to 12 months

    Will be examined in an exploratory manner, utilizing similar methods as those described for the primary endpoints for dichotomized versions of the outcomes, using standard cutoff values, where available.

  8. General health assessed using the patient-reported outcomes (PRO) survey

    Time frame: Up to 12 months

    Will be examined in an exploratory manner, utilizing similar methods as those described for the primary endpoints for dichotomized versions of the outcomes, using standard cutoff values, where available.

  9. Health behaviors assessed using the patient-reported outcomes (PRO) survey

    Time frame: Up to 12 months

    Will be examined in an exploratory manner, utilizing similar methods as those described for the primary endpoints for dichotomized versions of the outcomes, using standard cutoff values, where available.

  10. Health care utilization assessed using the patient-reported outcomes (PRO) survey

    Time frame: Up to 12 months

    Will be examined in an exploratory manner, utilizing similar methods as those described for the primary endpoints for dichotomized versions of the outcomes, using standard cutoff values, where available.

  11. Medications assessed using the patient-reported outcomes (PRO) survey

    Time frame: Up to 12 months

    Will be examined in an exploratory manner, utilizing similar methods as those described for the primary endpoints for dichotomized versions of the outcomes, using standard cutoff values, where available.

  12. Mood and worries assessed using the patient-reported outcomes (PRO) survey

    Time frame: Up to 12 months

    Will be examined in an exploratory manner, utilizing similar methods as those described for the primary endpoints for dichotomized versions of the outcomes, using standard cutoff values, where available.

  13. Musculoskeletal symptoms assessed using the patient-reported outcomes (PRO) survey

    Time frame: Up to 12 months

    Will be examined in an exploratory manner, utilizing similar methods as those described for the primary endpoints for dichotomized versions of the outcomes, using standard cutoff values, where available.

  14. Neuropathy assessed using the patient-reported outcomes (PRO) survey

    Time frame: Up to 12 months

    Will be examined in an exploratory manner, utilizing similar methods as those described for the primary endpoints for dichotomized versions of the outcomes, using standard cutoff values, where available.

  15. Post-traumatic stress assessed using the patient-reported outcomes (PRO) survey

    Time frame: Up to 12 months

    Will be examined in an exploratory manner, utilizing similar methods as those described for the primary endpoints for dichotomized versions of the outcomes, using standard cutoff values, where available.

  16. Quality of life assessed using the patient-reported outcomes (PRO) survey

    Time frame: Up to 12 months

    Will be examined in an exploratory manner, utilizing similar methods as those described for the primary endpoints for dichotomized versions of the outcomes, using standard cutoff values, where available.

  17. Reclassification of subject from high need to low need

    Time frame: At 6 months

    Reclassification of subject from high need to low need is defined as the high need subject no longer has scores above the cut-off level on 2 or more symptoms scales (depression, distress, insomnia, fatigue, pain) assessed using the PRO survey. The 5 symptom scales are categorized based on the following cut points to define "high need": pain score >= 5, fatigue score >= 3, insomnia score of no insomnia, distress score > 1.1, and depression score >= 10.

  18. Reproductive health assessed using the patient-reported outcomes (PRO) survey

    Time frame: Up to 12 months

    Will be examined in an exploratory manner, utilizing similar methods as those described for the primary endpoints for dichotomized versions of the outcomes, using standard cutoff values, where available.

  19. Sexual function assessed using the patient-reported outcomes (PRO) survey

    Time frame: Up to 12 months

    Will be examined in an exploratory manner, utilizing similar methods as those described for the primary endpoints for dichotomized versions of the outcomes, using standard cutoff values, where available.

  20. Social support assessed using the patient-reported outcomes (PRO) survey

    Time frame: Up to 12 months

    Will be examined in an exploratory manner, utilizing similar methods as those described for the primary endpoints for dichotomized versions of the outcomes, using standard cutoff values, where available.

Sponsors and collaborators

Lead sponsor

Fred Hutchinson Cancer Center

Other

Collaborators

  • Livestrong Foundation
  • National Cancer Institute (NCI)

Registry information

Official study title

Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14)

Important dates

Study start
2015
Primary completion
2017
Study completion
2019
First posted
Jul 16, 2014
Registry last updated
Oct 9, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.